BRCA1 and neoplasm: The clinical validation of F1CDx was based on a clinical bridging retrospective analysis of 368 patients included in SOLO1 whose tumor samples were available for analysis, of which 313 patients were determined to have a documented mutation in BRCA1/2 by F1CDx.